Combination therapy using antiangiogenic agents and TNFalpha

Details for Australian Patent Application No. 2002316855 (hide)

Owner Merck Patent GmbH

Inventors Grell, Matthias; Ruegg, Curzio; Goodman, Simon

Agent Davies Collison Cave

Pub. Number AU-B-2002316855

PCT Number PCT/EP02/04298

PCT Pub. Number WO2002/085405

Priority 01109981.9 24.04.01 EP

Filing date 18 April 2002

Wipo publication date 5 November 2002

Acceptance publication date 13 March 2008

International Classifications

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61K 38/00 (2006.01) Medicinal preparations containing peptides

A61K 38/19 (2006.01) Medicinal preparations containing peptides - Cytokines

A61K 38/21 (2006.01) Medicinal preparations containing peptides - Interferons

A61K 38/22 (2006.01) Medicinal preparations containing peptides - Hormones

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 35/00 (2006.01) Antineoplastic agents

A61P 35/04 (2006.01) Antineoplastic agents

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

Event Publications

9 January 2003 Complete Application Filed

  Priority application(s): 01109981.9 24.04.01 EP

17 April 2003 Application Open to Public Inspection

  Published as AU-B-2002316855

13 March 2008 Application Accepted

  Published as AU-B-2002316855

10 July 2008 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002316856-METHOD AND DEVICE FOR TREATING A FIBER MASS

2002316854-PROCESS FOR THE PRODUCTION OF CITALOPRAM